Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Down 3.7% – Time to Sell?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)’s stock price fell 3.7% during trading on Friday . The company traded as low as $3.64 and last traded at $3.64. 87,011 shares changed hands during trading, a decline of 95% from the average session volume of 1,889,799 shares. The stock had previously closed at $3.78.

Analysts Set New Price Targets

Separately, StockNews.com downgraded shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $10.40.

Ironwood Pharmaceuticals Trading Down 3.8 %

The firm has a market capitalization of $581.71 million, a price-to-earnings ratio of -121.17 and a beta of 0.34. The stock’s 50-day moving average is $3.99 and its 200-day moving average is $4.68.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The company had revenue of $91.60 million for the quarter, compared to analyst estimates of $91.22 million. During the same quarter last year, the company posted $0.12 earnings per share. The firm’s quarterly revenue was down 19.4% on a year-over-year basis. On average, equities research analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.08 EPS for the current fiscal year.

Insider Activity

In related news, CFO Sravan Kumar Emany sold 11,001 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $4.08, for a total transaction of $44,884.08. Following the completion of the transaction, the chief financial officer now directly owns 309,572 shares of the company’s stock, valued at $1,263,053.76. This trade represents a 3.43 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 12.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. KBC Group NV boosted its position in Ironwood Pharmaceuticals by 59.3% during the third quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 3,198 shares during the last quarter. Diversified Trust Co acquired a new stake in Ironwood Pharmaceuticals during the third quarter worth approximately $52,000. Wolverine Trading LLC bought a new stake in Ironwood Pharmaceuticals in the third quarter worth approximately $51,000. Algert Global LLC acquired a new position in Ironwood Pharmaceuticals in the second quarter valued at approximately $93,000. Finally, Legacy Capital Group California Inc. bought a new position in shares of Ironwood Pharmaceuticals during the 3rd quarter worth approximately $59,000.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.